Synthesis of novel 5-(2,5-bis(2,2,2-trifluoroethoxy) phenyl)-1,3,4-oxadiazole-2-thiol derivatives as potential glucosidase inhibitors

Background: A hybrid molecule of different biologically active substances can improve affinity and efficiency compared to a standard drug. Hence based on this fact, we predict that a combination of fluorine, oxadiazole, sulfur, etc., may enhance alpha-glucosidase inhibition activity compared to a standard drug. Methods: A series of novel 5-(2,5-bis(2,2,2-trifluomethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives (2a-2i) were synthesized and characterized using spectroscopic techniques such as (HNMR)-H-1 and LC-MS. In order to evaluate its bioactivity, in vitro alpha-amylase and alpha-glycosidase inhibitory activity were performed. In vivo study was carried using a genetic model, Drosophila melanogaster, for assessing the antihyperglycemic effects. Results: The compounds 2a-2i demonstrated a-amylase inhibitory activity in the range of IC50 = 40.00-80.00 mu g/ml as compare to standard acarbose (IC50 = 34.71 mu g/ml). Compounds 2a-2i demonstrated alpha-glucosidase inhibitory activity in the range of IC50 = 46.01-81.65 mu g/ml as compared to standard acarbose (IC50 = 34.72 mu g/ml). Docking studies on a target protein, N-terminal subunit of human Maltase-glucoamylase (PDB:2QMJ) was carried and the compounds were found to dock into the active site of the enzyme (Fig. 1). The predicted binding energies of the compounds were calculated. The in vitro studies indicate that compounds 2b and 2g had better activity among the synthesized compounds. Whereas in vivo study indicates that 2b, 2g, and 2i could lower glucose levels in the Drosophila, but then 17-30% reduced capacity than acarbose and may be overcome by adjusting their dosage. Conclusions: The in vitro and in vivo studies indicate that compounds 2b and 2g had better activity among the synthesized compounds. This study has recognized that compounds like 2b, 2g, and 2i may be considered potential candidates for further developing a novel class of antidiabetic agents.